Our vision is to set new standards for nucleic acid extractions, and, fundamentally and forever, change how sample preparation is done in clinical and research labs.
Our mission is to drive the advancement of personalized cancer medicine and improved future management of cancer patients and related research.
In a world observing increased number of cancer patients, a shorter time from sample collection to diagnosis is highly important.
Increase productivity with minimal hands-on time with fully automated extraction protocols
Make the most of your sample with serial extraction of DNA and RNA from the same specimen
ExScale introduces automated, next generation technology for nucleic acid extraction from formalin-fixed, paraffin-embedded (FFPE) tissue sections using paramagnetic beads. The technology enables serial extraction of DNA and RNA from the same biospecimen where the isolated nucleic acids are of optimal quality for next generation sequencing and other downstream applications.
ExScale Biospecimen Solutions is a Swedish company specializing in processes and know-how for nucleic acid extraction from human tissue specimens. The company was established in 2012 by researchers at Uppsala University and has since then developed and marketed their Next Generation Extraction technology, NGEx, defined by innovative new methods and products for automated nucleic acid extractions.
ExScale has implemented a quality management system according to ISO13485 with CE marked products according to Directive 98/79/EC.
ExScale introduces an automated next generation technology for nucleic acid extraction from fresh-frozen and formalin-fixed, paraffin-embedded (FFPE) tissue sections using paramagnetic beads. The technology enables sequential extraction of DNA and RNA from the same biospecimen. The isolated nucleic acids are suitable for use in NGS and other downstream applications for clinical and research purposes.
ExScale’s nucleic acid isolation protocols use intuitive software, novel lysis buffer solutions and magnetic separation of DNA and RNA-bound bead particles enabling standalone DNA/total RNA or proprietary serial extraction of both DNA and RNA from the same tissue sample. ExScale’s purification kits consist of plastic-ware, reagents packed into prefilled cartridges and a deparaffinisation reagent.
ExScale’s purification technology utilizes a convenient bench-top Magtration® System magLEAD 12GC and 12GC Plus/UV robots (Precision System Science Co.,Ltd.) or Freedom EVO® workstation (Tecan) with the ability to simultaneously process up to 12 samples (Magtration® system) or 96 samples (Freedom EVO®).
The Magtration® Technology platform enables separation and re-suspension of magnetic beads within a disposable tip, reducing the risk for cross contamination between samples.
|ExScale NGEx kit|
|FFPE DNA||FFPE Total RNA||FFPE serial DNA and total RNA||Fresh-frozen serial DNA and total RNA|
|Automated extraction on 12-channel instrument||ES-K110FP-C*||ES-K210FP**||ES-K110210FP-C*||ES-K110210F**|
* CE marked according to IVD 98/79/ec
** For laboratory use only
The FFPE DNA Purification Kit is optimized for rapid and efficient purification of genomic DNA from FFPE tissue samples. Purified DNA is of high yield and quality and is suitable for use in next generation sequencing, real time RT-PCR, PCR and other downstream application. The protocol requires a total run time of 3 hours 40 mins.
The FFPE Total RNA Purification Kit allows a rapid and efficient extraction of total RNA from FFPE tissue samples. Tissue deparaffinisation is safely and effectively achieved without the use of organic solvents. Purified RNA is of optimal quality for next generation sequencing, real time RT-PCR, PCR and other downstream applications. The protocol requires a total run time of 2 hours 15 mins.
The FFPE DNA/RNA Purification Kit is optimized to allow the sequential purification of genomic DNA and total RNA from the same FFPE tissue sample. DNA and total RNA are of suitable quality for next generation sequencing, real time RT-PCR, PCR and other downstream application, with a total run time of 3 hours 10 min (short lysis) or 4 hours 30 mins (long lysis).
This kit is optimized to allow the sequential purification of genomic DNA and total RNA from the same fresh-frozen tissue sample embedded in OCT or up to 1 million cells. The kit contains prefilled reagents cartridges and consumables for the fully automated extraction process. DNA and total RNA are of suitable quality for next generation sequencing, real time RT PCR, PCR and other downstream application. This protocol is designed to minimize hands-on time and has a total turnaround time of 2 hours 15 mins.
To place an order, please contact us.
Disclaimer: The ExScale Biospecimen products are currently not available for commercial distribution in the US.
ExScale has an experienced management team and a board with a proven entrepreneurial track record. The team also has a global network of health care providers, and regulatory, design and production partners.
Manoush Masarrat has more than 15 years of experience in the Medical Device arena that includes leadership of high performing teams in the areas of Sales, Marketing and New Product Development. Manoush joined the ExScale team from Medical vision where he served as the Executive VP in Sales & Marketing. Prior to that, he worked at ElectroCore AB as their European CEO. He has also held a number of senior sales and marketing roles at ArthroCare Corporation over the 9 years he worked there. Manoush holds a BSc In industrial Economics from Gävle, Sweden, as well as international studies on Master level from UK and Australia.
Sten Dahlborg has more than 25 years of international board and executive management experience in private start-up and public companies within the life science sector. In addition to his role as CEO of ExScale, Sten serves as a board director for a few companies within and outside the life science sector. Prior to joining ExScale, Sten served as the Senior Vice President and President for ArthroCare Corporation (NASDAQ: ARTC), and as the President for Medtronic Synectics Medical, Inc. (NYSE: MDT). Sten has a M. Sc. degree in Engineering Physics from Chalmers University of Technology.
Anna Pettersson has several years of experience from management positions in companies in the life science industry; Synectics/Medtronic, ArthroCare Corp and ElectroCore LLC. She has gained experience from phases of start up through expansion – organic and acquisitions within infrastructure projects, marketing communication platforms, business practice and compliance as well as investor relations. She studied Information, Communication and Public Relations at the Institute of RMI Berghs and International Relations/Executive Assistant through the Stockholm University.
Anders Holmberg has more than 25 years of international research and development expertise in the field of DNA/RNA sequencing and extraction. He has co-founded several biotechnology companies and worked in private start-up and public companies within the life science sector. In addition to his role in Business Development for ExScale, he serves as a board director for companies within and outside the life science sector. Prior to joining ExScale, Anders served as CEO for Nordiag AB and as CSTO of Precision Systems Science, Japan.
Lucy Mathot is a postdoctoral researcher from the Department of Immunology, Genetics and Pathology at Uppsala University, Sweden. Lucy possesses broad experience in DNA and RNA extraction from tumors, whole blood and cultured cells, and extensive knowledge in different DNA and RNA-based diagnostic methods. Lucy co-founded ExScale™ in 2012.
With training in both business administration and biomedicine, Karin Hartman brings important competence in business and enterprise in the life science sector. She has broad experience in DNA and RNA extraction from tumors and cultured cells and possesses extensive knowledge in the field of molecular diagnostics.
Ammar Zaghlool is a postdoctoral researcher from the Science for Life Laboratory at Uppsala University, Sweden. Ammar has significant knowledge in applying, adapting and developing methods and technologies to enable comprehensive understanding of transcriptomes in health and disease, with extensive experience in genetic screening techniques. Ammar also has professional training in project management.
Björn Ekström has many years of experience as a senior manager in several biotech companies including Pyrosequencing AB, Olink AB (where he was also a co-founder) and Pharmacia Biotech (now GE Healthcare). He has also served on the board of directors for a number of companies in the life science field over the years. Dr. Ekström holds an MSc in Physical Biochemistry from The Institute of Technology, Lund, Sweden and is appointed an honorary doctorate by the Faculty of Medicine at Uppsala University.
Tobias Sjöblom is Associate Professor at the Department of Immunology, Genetics and Pathology at Uppsala University, Sweden. With over 15 years of experience from cancer research, Tobias brings invaluable competence and knowledge about clinical demands and novel methods for screening, diagnostics and therapy. Tobias co-founded ExScale™ in 2012.
Liang Wei Min has more than 25 years of sales experience in the medical field, specifically in laminar flow systems for operating theatres. He has built a strong network in the Chinese market through the introduction of some of the latest applications in medical products such as the linear accelerator. Liang Weimin was a medical doctor with 15 years of clinical experience in China.
Simon Grant has extensive experience within the medical device industry, especially with diagnostic devices where he has focused on commercialization of new clinical technologies. Simon has held senior positions within management and sales and marketing in medtech startups such as Synectics Medical and Neoventa, and in established multinationals such as Medtronic. He has always worked with an international focus, and has been based in Scandinavia, the US and Asia.
Allan Asp is investment manager at ALMI Invest AB, and possesses a long experience from marketing activities at life science companies like Pharmacia, Pyrosequencing and Alphahelix AB. He serves in the board of directors of Gradientech AB, Chromafora AB and WaveCraft i Uppsala AB.
Sten Dahlborg has more than 20 years of international board and executive management experience in private start-up and public companies within the life science sector. In addition to his role as CEO of ExScale, Sten serves as a board director for a few companies within and outside the life science sector. Prior to joining ExScale, Sten served as the Senior Vice President and President for ArthroCare Corporation (NASDAQ: ARTC), and as the President for Medtronic Synectics Medical, Inc. (NYSE: MDT). Sten has a M. Sc. degree in Engineering Physics from Chalmers University of Technology.
Lars Jonsson has 19 years of experience as CEO of Uppsala University Holding Company, an early seed-investor controlled by the university. With a background as both an MD and Hospital Director, he combines the practical experience of health care with the experience of commercializing science from more than 60 university spin-offs including several board memberships.
ExScale believe in a business culture where our employees can develop, both as individuals and in teams. We consider each person’s background and competence as strengths that can add creative solutions to the team as well as to the interactions with our customers, distributors and collaborators. Our employees are trained to work in many different environments with the same passion and goal in mind, which we believe creates knowledge and well-rounded individuals. If you are interested in being a part of our team, please forward your CV to email@example.com.
Do you share our vision and understanding of nucleic acid extractions and/or personalized medicine? ExScale welcomes your interest in collaboration with us by submitting a short description to firstname.lastname@example.org.
New understanding about the genetic composition of different cancer types has led to tailored cancer treatments using molecular diagnostic tests. Applicable to many aspects of patient management including diagnosis, prognosis and response to therapy; molecular diagnostic tests offer new hope for patients battling cancer, saving them from unnecessary toxicity while improving treatment outcome. One critical aspect in molecular diagnostics is related to the quality of the results, which depends largely upon the quality of genetic input material used, i.e. DNA and RNA. Currently, there is a demand for robust and automated solutions for extracting nucleic acids; DNA and RNA, without compromising on quality. To meet this growing need, ExScale have developed the Next Generation Extraction technology NGEx. NGEx is a novel technology which sets new standards for nucleic acid extraction and improves productivity for personalized medicine.
ExScale intends to have a leading position in the markets in which we compete and to meet needs and preferences from our key stakeholders, including hospitals, research departments and industry. We are positioned to grow together with the major market trends where we believe that our sequential DNA and RNA extraction technology will help drive the progression of personalized cancer medicine.
Viruses in case series of tumors: Consistent presence in different cancers in the same subjectArroyo Mühr, L. S. et al. PLOS ONE 12, e0172308 (2017)
Efficient and scalable serial extraction of DNA and RNA from frozen tissue samplesMathot L, Lindman M, Sjöblom T. Chem Commun 2011;47:547-9.
Automated serial extraction of DNA and RNA from biobanked tissue specimensMathot L, Wallin M, Sjöblom T. BMC Biotechnol, 13, 66.